- Mabwell’s subsidiary T-mab has signed a licensing deal with Qilu Pharmaceutical for Albipagrastim alfa (R&D code: 8MW0511) across Greater China
- As per the deal, Mabwell will grant Qilu exclusive rights to develop, manufacture, improve, utilize, and commercialize Albipagrastim alfa in Greater China(including the Chinese Mainland, Hong Kong, Macau, and Taiwan). T-mab will receive up to RMB 500M ($69.71M) in upfront and milestone payments, plus up to double-digit royalties on net sales
- Albipagrastim alfa is a recombinant yeast-secreted fusion protein of human serum albumin and G-CSF(I) used to reduce febrile neutropenia in adults with non-myeloid cancers undergoing myelosuppressive CT
Ref: Prnewswire | Image: Mabwell | Press Release
Related News:- Vor Bio Enters a ~$4.12B Exclusive Global License Agreement with RemeGen to Develop and Commercialize Telitacicept
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
